B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $46
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
B of A Securities analyst Alec Stranahan maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $40 to $46.
B of A Securities analyst Alec Stranahan maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $40 to $46.